Introduction: The REGAL (RSV Evidence-a Geographical Archive of the Literature) series provide a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This second publication covers the risk and burden of RSV infection in preterm infants born at \37 weeks' gestational age (wGA) without chronic lung disease or congenital heart disease. Methods: A systematic review was undertaken for articles published between January 1, 1995 and December 31, 2015. Studies reporting data for hospital visits/admissions for RSV infection among preterm infants as well as studies reporting RSV-associated morbidity, mortality, and risk factors were included. Study quality and strength of evidence (SOE) were graded using recognized criteria. Results: 2469 studies were identified of which 85 were included. Preterm infants, particularly Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ F6E4F06044E2A44B. Electronic supplementary material The online version of this article (
INTRODUCTION
Respiratory syncytial virus (RSV) is the most important cause of severe respiratory infection in infants, leading to over 3 million hospitalizations worldwide each year [1] . By 2 years of age, almost all children have been infected with RSV at least once [2] . Although the majority of severe cases occur among previously healthy term infants [3, 4] , clinical studies have shown that infants with a history of prematurity are at higher risk of RSV infection requiring hospitalization than infants born at term [4, 5] . The risks relate to anatomic factors including small lung volumes, a reduced lung surface area, small airways, an increased air space wall thickness, and lower levels of maternally transmitted antibodies [6] .
Although prematurity alone can significantly increase the risk for severe RSV disease, the presence of one or more other socioeconomic and environmental risk factors may also increase an infant's susceptibility to severe RSV disease and subsequent hospitalization [7] [8] [9] [10] [11] [12] . Every year, an estimated 15 million infants are born preterm (before 37 completed weeks of gestation), and according to the World Health
Organization, this number is rising [13] . In developed countries, almost 9% of all live births annually are estimated to be preterm, with those born between 32 and 37 weeks' gestational age (wGA) representing the majority ([80%) of preterm infants [13] . Care of preterm infants with severe RSV disease places a substantial burden on pediatric hospital resources each winter [14] . Data from a 2003 retrospective study suggest that prematurity B35 wGA is a risk factor for greater use of hospital resources and poorer clinical outcomes during hospitalization for severe RSV infection [14] . In addition, RSV infection in preterm infants has been associated with chronic respiratory morbidity and increased healthcare costs [15] [16] [17] [18] [19] .
Currently, no effective vaccine against RSV exists, but RSV immunoprophylaxis is available for certain high-risk groups to prevent RSV disease. A number of underlying risk factors that significantly increase the risk of RSV hospitalization (RSVH) in preterm infants have been identified [20] , most notably from the Spanish FLIP (Factors that most Likely may lead to development of RSV related respiratory Infection and subsequent hospital admission among Premature infants born 33-35 wGA) [7, 8] and the Canadian PICNIC (The Pediatric Investigators Collaborative Network on Infections in Canada) [9] studies. Many of these risk factors have been used to inform national guidance on the optimal use of RSV immunoprophylaxis in different countries including the United States (US) [21] , Canada [22] , Spain [23] and Italy [24] . The prevention of RSV in preterm infants, however, continues to be a challenge. A greater awareness of the relative importance of prematurity as a risk factor for severe RSV disease is essential in order to improve patient outcomes and reduce the burden on healthcare systems. Geographical Archive of the Literature (REGAL) was to carry out a series of systematic reviews and then to assess, quantify, summarize and grade the evidence base for severe RSV infection in Western societies. By undertaking this review, our current understanding of RSV was defined as well as, importantly, gaps in our knowledge and future areas of research.
This paper, which represents the second in a series of seven publications covering a range of topics on RSV disease, identifies and describes the risks and associated morbidity and mortality of severe RSV infection requiring hospitalization in preterm infants without chronic lung disease (CLD)/bronchopulmonary dysplasia (BPD) or congenital heart disease (CHD) in Western societies.
METHODS
The primary objective of REGAL was to address seven specific research questions. The systematic reviews undertaken to answer each research question all used the same broad methodology, which has been described elsewhere [25] . The full protocol and generic search terms for the systematic reviews are available as part of the online supplement. In brief, we conducted a systematic and comprehensive search of medical literature electronically indexed in PubMed, EMBASE, the Cochrane Library, and clinicaltrials.gov.
We used a detailed search strategy and combined free-text search terms with Medical Subject Headings. To ensure that the literature search was manageable, only studies conducted in Western countries were included, defined as the US, Canada, and Europe (including Turkey and the Russian Federation).
The search for this systematic review included studies conducted in children (defined as B18 years old) and published between January 1, 1995 and December 31, 2015. The target population was preterm infants born at less than 37 wGA without CLD or CHD (or studies with mixed populations of healthy preterm infants and preterm infants, some with comorbidities) who had 'proven' or 'probable' RSV and had or had not received RSV immunoprophylaxis. Other significant studies of the target population, published during the drafting of the manuscript, were also included in the review, as identified by the authors.
In this systematic literature review, we sought to answer the two following questions: 
Evaluation of Data
Included publications were graded according to the Oxford Centre for Evidence-Based Medicine Levels of Evidence [26, 27] (Supplementary Material 1-REGAL Protocol). For each study, we conducted a risk of bias assessment using the RTI Item Bank (score of 1 = very high risk of bias; score of 12 = very low risk of bias) for observational studies [28] . No quantitative data synthesis was conducted due to heterogeneity between studies in terms of design, patient populations, RSV testing, recording and availability of outcomes, and differences in clinical practice between countries and over time.
Compliance with Ethics Guidelines
The analysis in this article is based on previously published studies and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS

Articles Selected
From a total of 2469 publications, 85 studies were included in the final review: 76 identified from the database searches and a further 9 from reference lists/other sources ( Fig. 1 ). Data extraction tables for all 85 studies, including evidence grades and risk of bias assessments can be found in the online supplement (supplementary material 2).
Incidence of RSVH in Preterm Infants
Both prospective and retrospective population-based studies performed in the US, Canada and Europe have demonstrated that infants with a history of prematurity are at increased risk for RSVH [3] [4] [5] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] . Preterm infants, particularly those born at lower gestational ages, tended to have higher rates of hospitalization for RSV compared to otherwise healthy term infants [4, 5, 31, 37, 43, [47] [48] [49] [50] [51] . In a 5-year prospective, population-based study, very preterm infants (\30 wGA) accounted for only 3% of RSV cases, but had RSVH rates three times that of term infants [4] . In the French CASTOR (Comparison of the rAte of hoSpitalization for RSV bronchiolitis between preterm infants born at 32 wGA or less without BPD and full-teRm infants) study, preterm infants had a fourfold increased risk of hospitalization for RSV bronchiolitis compared to the matched full term group (95% confidence interval [CI]: 1.36-11.80) [50] . In the Dutch LOLLIPOP (Longitudinal Preterm Outcome Project) study (ClinicalTrials.gov identifier: ISRCTN80622320) [43] , the rates of RSVH were found to be higher in preterm infants 32-36 wGA than full term infants (3.9% vs. 1.2%, relative rate [RR]: 3.2; 95% CI: 1.4-7.1, P = 0.003), but similar to that among preterm infants \32 wGA (3.9% vs. 3.2%, RR: 1.2, 95% CI: 0.7-2.1, P = 0.50) and higher than that among full term infants. Overall, rates of RSVH tended to be around 3 times higher in premature than term infants, albeit with considerable heterogeneity across studies (range 1.1-8.1 times higher) [5, 31, 37, 43, [47] [48] [49] [50] [51] . In these studies, the majority of preterm infants were previously healthy, providing evidence that preterm infants without underlying conditions, such as CLD (BPD) and CHD, are at increased risk of developing severe RSV infection.
RSVH rates for preterm infants over the last two decades vary in the literature [4, 5, 8-12, 29, 31, 37, 47, 49, 51-57] , ranging from *5/1000
children [4] to [100/1000 children [52, 53] , with the highest RSVH rates reported in the lowest gestational age infants (Table 1 ). In the majority of these studies, RSV immunoprophylaxis was not given. In the Dutch RISK [10] and RISK-II [11] studies, the overall RSVH risk for healthy preterm infants born at 33-35 wGA was 51/1000 children and 35/1000, respectively. In Austria, the overall RSVH risk for infants born at 29-32 wGA was 45/1000 children. RSV immunoprophylaxis was given to 29.7% infants, but almost half of these received inadequate or incomplete courses [56] .
In the PICNIC study [9] , the RSVH rate for infants born at 33-35 wGA was 36/1000 children, although center and seasonal variation in hospitalization rates for RSV infection were observed. A more recent study of 32-35 wGA infants followed prospectively from September to May 2009-2010 or 2010-2011 in the US [57] , found that the observed hospitalization rate (49/1000 infant-seasons) was similar to that reported in other studies conducted outside the US that employed active surveillance for laboratory-confirmed RSV [9, 44] . In the PONI study [12] , a multinational study ( [60] , which enrolled three different gestational age group infants (\29, 29 to \32 and 32-35 wGA), found that the percentage of hospitalized preterm infants B12 months old that were RSV positive progressively decreased from 40.0% to 28.6% and 18.4% with increasing wGA (P = 0.43). These data suggest that, at least in the first year of life, the most premature infants were more vulnerable and prone to RSV infection [60] . Further data from a post hoc analysis of the Spanish FLIP 2 study [8] indicate that the risk of RSV-related hospitalization is maintained in many preterm infants born at 32-35 wGA up to at least 6 months old and baseline risk factors continue to contribute varying risk over the infants first year of life [61] . These findings may have implications for future prevention strategies and the authors suggest that further prospective studies be undertaken to fully explore the changing risk of RSVH during the first year of life in preterm infants [61] . Children with a history of prematurity are at a higher risk of worse hospital outcomes (use of supplemental oxygen, NICU admission) for RSV infection than term infants [5, 8, 12, 14, 24, 46, 49, 50, 57, 58, 64-72, 74, 75] . In the French CASTOR study, preterm infants \33 wGA were prone to more severe disease as suggested by longer hospital stays and the requirement of more therapeutic care, including oxygen therapy and non-mechanical ventilation, compared with the full-term group [50] . Similarly, a retrospective study conducted in Central and Eastern Europe (CEE) reported that, among RSV-positive patients, premature children (\37 wGA) had a significantly longer hospital stay (17 vs. 8 days; P\0.001), were more frequently hospitalized in the ICU (41.4% vs. 12.6%), and remained in the ICU significantly longer (13 vs. 6 days; P\0.001) compared with term children [46] . In a Canadian study, Sampalis [64] intravenous antibiotics or admission to the ICU) in the first 5 days after disease onset [76] .
In contrast to other studies, while admission to the ICU was associated with a history of premature birth (odds ratio [OR]: 1.7; 95% CI:
1.1-2.4, P = 0.01), Sala et al. [77] found no significant difference in the ICU LOS (106 [14] and Willson [75] used different subsets of the same baseline dataset RSV-related illness [14, 16, 24, 31, 50, 57, 79, 80] , and up to 75% are admitted to the ICU, depending on gestational age [12, 14, 16, 46, 50, 57, 72, 74] .
In addition to the acute burden placed on pediatric services during the winter season, RSVH has been associated with on-going respiratory morbidity. This will be covered in a subsequent publication in the REGAL series.
Gestational Age-Specific Complications and Hospital Resource Use
Severe RSV infection in preterm infants \37
wGA has been shown to result in substantial morbidity associated with hospitalization, but few studies have characterized RSV-confirmed hospitalizations in this high-risk population.
Consistent
with previous studies [5, 14, 49, 57, 58, 65] , recently published data from the ongoing SENTINEL1 study (ClinicalTrials.gov identifier: NCT02273882) [74, 81] demonstrated that earlier gestational age and younger chronologic age were associated with a higher risk of ICU admission and need for mechanical ventilation compared with birth at later gestational age and older chronologic age ( the gestational groups studied [75] .
In addition to the associated morbidity,
RSVH costs for preterm infants have been
shown to be substantial at follow up [16] [17] [18] [82] [83] [84] . In a retrospective cohort study undertaken in the US, preterm infants born at 33-36 wGA with a RSVH incurred $21,977 higher costs (P\0.001) compared with corresponding controls without RSVH during their first year of life [82] . In another retrospective study in the UK, RSVH was associated with a significant increase in the health-related cost of care in the first 2 years after birth in infants born between 32 and 35 wGA. The mean cost of care in the RSV group (£12,505) was greater than the non-respiratory (£1178) (95% CI for difference £5015 to £17,639, P\0.002) and the other respiratory (£3356) groups (95% CI for difference £2963 to £15,606, P\0.001) [16] . It has been calculated that over the first year of life, 33-36 wGA and \33 wGA infants hospitalized with RSV go on to incur healthcare costs almost five times and three times higher, respectively, than preterm infants with no history of RSV infection [85] . In a further study undertaken in the Netherlands, estimated mean hospitalization costs for RSV were highest for patients with lower gestational age (€5555, B28 wGA) as a result of a longer duration of hospitalization [83] . These findings highlight the importance of preventive strategies in this high-risk group.
Case-Fatality Rates
Severe RSV infection is an important cause of childhood mortality worldwide [1] . However, few studies in the published literature on RSVH report case-fatality rates in preterm infants and therefore it is difficult to ascertain from the available data the precise number of true RSV deaths in this high-risk population. Two studies undertaken in the US [86] and Canada [64] in the early 2000s reported that RSVH in healthy premature infants is associated with increased mortality. Leader et al. [86] found that low birth weight and/or prematurity (B35 wGA) independently increased the risk of post-neonatal RSV-associated death in children. Case-fatality rates were 43/100,000 for infants without comorbidities born at B35 wGA and weighing \2500 g compared with 20.3/100,000 for infants without comorbidities born at C37 wGA and weighing \2500 g (total number of deaths recorded in infants without comorbidities: 288) [86] . Sampalis [64] [8] studies; the Canadian PICNIC [9] study; the Dutch RISK [10] and RISK-II [11] studies; and the multinational PONI study [12] . Independent risk factors for RSVH reported in these studies cover exposure (proximity of birth to the RSV season, living with school-age siblings, crowding at home, day care attendance), social factors (mother smoking during pregnancy, smoking around infants, reduced breast feeding), biological factors (small for gestational age, male sex, familial wheezing and atopy, young maternal age, low maternal education), and medical factors (neonatal respiratory support, short hospital stay at birth) ( Table 4 ) [7] [8] [9] [10] [11] [12] . In addition, a further analysis using data from several datasets, including the FLIP study [7] and the FLIP-2 study [8] showed that preterm infants born at 32-35 wGA from smoking families appear to be at heightened risk for severe RSV infection requiring hospitalization [90] . In this study, there were 2.35 times (95% CI 1.37-4.02) as many hospitalizations amongst infants from smoking compared with those from non-smoking families [90] .
Several predictive models have been developed from these six studies, using between 4 and 7 risk factors, to predict those premature infants at highest risk of RSVH [10] [11] [12] [91] [92] [93] (Table 5 ). The areas under the receiver operating characteristic (ROC) curves ranged from 0.687 to 0.791 for the six models [10] [11] [12] [91] [92] [93] , representing fair to good predictive accuracy (0.50-0.75 = fair, 0.75-0.92 = good, 0.92-0.97 = very good, and 0.97-1.00 = excellent) [94] . All the models except the ones derived from the PONI dataset [12] have been externally validated [10, 11, 92, [95] [96] [97] . In three of the six models (FLIP [7] , FLIP 2 [8] and PICNIC [10] ), age at the start of the RSV season was the most predictive variable. In the RISK and RISK-II models [10, 11] , the presence of siblings or the subject attending day care was the most predictive variable (age was the second most predictive).
A prospective evaluation of the PICNIC model found it reduced hospitalization in infants most 'at-risk' while avoiding RSV immunoprophylaxis in a large segment (81.9%) of 33-35 wGA infants considered at low risk for RSV infection [98] .
Further data on risk factors in this specific gestational-age group come from the REPORT study [57] . Consistent with previous observations in the RISK study [10] , overall RSV disease risk in infants 32-34 and 35 wGA 
Risk factors
Odds ratio (95% confidence interval) FLIP study [7] (n 5 557) FLIP-2 study [8] (n 5 5441) PICNIC study [9] (n 5
1758)
RISK study [10] (n 5 2421) RISK-II study [11] (n 5
1564)
PONI study [12] (n 5
2390)
Exposure Age Table 4 continued
Risk factors
1758)
1564)
2390)
Male [43] .
CONCLUSIONS
The impact of severe RSV infection in high-risk groups is important in planning preventive strategies. Findings of this review confirm that the risk for severe RSV disease is significantly increased in preterm infants \37 wGA, which can result in substantial morbidity associated with hospitalization (Summary Box). In the majority of these studies, the preterm infants were previously healthy, providing evidence that criteria for authorship for this manuscript, take responsibility for the integrity of the work as a
Summary box
Level of evidence a
Key statements/findings
Studies have shown that preterm infants, particularly those born at lower gestational ages, are at high risk for RSVH and tended to have higher rates of hospitalization for RSV compared with otherwise healthy term infants A number of independent risk factors associated with RSVH in premature infants have been reported including exposure (e.g. proximity of birth to the RSV season, living with school-age siblings), social factors (e.g. smoking of mother during pregnancy or environmental smoking, reduced breast feeding), and biological factors (e.g. male sex, familial asthma) 1 (Level 1 studies: n = 6; risk of bias b : 11.0)
Predictive models for RSVH in 32-35 wGA infants have been developed using 4 or 7 risk factors with areas under the ROC curves ranging from 0.687 to 0.791 (fair to good predictive accuracy) 1 (Level 1 studies: n = 6; risk of bias b : 11.0)
Key areas for research
In light of the continuing burden and long-term sequelae of severe RSV infection in otherwise healthy preterm infants, further research is needed on gestation-specific prevalence and burden of RSV disease to confirm the vulnerability of these children
Further prospective studies should be undertaken to fully explore the changing risk of RSVH during the first year of life in preterm infants ICU intensive care unit, ROC receiver operating characteristic, RSV(H) respiratory syncytial virus (hospitalization), wGA weeks' gestational age a Level 1: Local and current random sample surveys (or censuses); Level 2: Systematic review of surveys that allow matching to local circumstances; Level 3: Local non-random sample; Level 4: Case-series [26, 27] b Average RTI Item Bank Score [28] , where 1 = very high risk of bias and 12 = very low risk of bias whole, and have given final approval to the version to be published.
Disclosures. The institute of Louis Bont received money for investigator initiated studies by MeMed, Astra Zeneca, AbbVie, and Janssen. The institute of Louis Bont received money for consultancy by Astra Zeneca, AbbVie, MedImmune, Janssen, Gilead and Novavax. Paul Checchia has acted as an expert advisor and speaker for AbbVie and has received honoraria in this regard. He has also received research grant funding from AstraZeneca.
Brigitte Fauroux has received compensation as a neonatology board member from AbbVie. 
